

CASE REPORT

Open Access

Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report

Conceição Bettencourt^{1,2,3,4*}, Cristina Santos⁵, Paula Coutinho^{3,6}, Patrizia Rizzu⁷, João Vasconcelos⁸, Teresa Kay⁹, Teresa Cymbron^{1,2,3}, Mafalda Raposo^{1,2}, Peter Heutink⁷ and Manuela Lima^{1,2,3}

Abstract

Background: Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), is an autosomal dominant neurodegenerative disorder of late onset, which is caused by a CAG repeat expansion in the coding region of the *ATXN3* gene. This disease presents clinical heterogeneity, which cannot be completely explained by the size of the repeat tract. MJD presents extrapyramidal motor signs, namely Parkinsonism, more frequently than the other subtypes of autosomal dominant cerebellar ataxias. Although Parkinsonism seems to segregate within MJD families, only a few MJD patients develop parkinsonian features and, therefore, the clinical and genetic aspects of these rare presentations remain poorly investigated. The main goal of this work was to describe two MJD patients displaying the parkinsonian triad (tremor, bradykinesia and rigidity), namely on what concerns genetic variation in Parkinson's disease (PD) associated loci (*PARK2*, *LRK2*, *PINK1*, *DJ-1*, *SNCA*, *MAPT*, *APOE*, and mtDNA *tRNA^{Gln}* T4336C).

Case presentation: Patient 1 is a 40 year-old female (onset at 30 years of age), initially with a pure parkinsonian phenotype (similar to the phenotype previously reported for her mother). Patient 2 is a 38 year-old male (onset at 33 years of age), presenting an ataxic phenotype with parkinsonian features (not seen either in other affected siblings or in his father). Both patients presented an expanded *ATXN3* allele with 72 CAG repeats. No PD mutations were found in the analyzed loci. However, allelic variants previously associated with PD were observed in *DJ-1* and *APOE* genes, for both patients.

Conclusions: The present report adds clinical and genetic information on this particular and rare MJD presentation, and raises the hypothesis that *DJ-1* and *APOE* polymorphisms may confer susceptibility to the parkinsonian phenotype in MJD.

Background

Autosomal dominant cerebellar ataxias (ADCA) constitute a heterogeneous group of neurodegenerative disorders, which involve, besides other systems, the extrapyramidal system in a highly variable manner. Within this group is Machado-Joseph disease (MJD; MIM #109150), also known as spinocerebellar ataxia type 3 (SCA3), that presents extrapyramidal motor signs (EPS) more frequently than the other subtypes of ADCA [1]. Even within MJD, the EPS may vary, sometimes with marked dystonic postures, others with isolated parkinsonian features or even, though rarely, with the parkinsonian triad (resting tremor, bradykinesia and

rigidity) [2]. Although the causative mutation of MJD is known to be an expansion of a CAG repeat motif (consensually more than 52 repeats) in the coding region of the *ATXN3* gene [3], the size of the of the repetitive tract does not completely explain the clinical heterogeneity observed in this disorder, namely concerning the presence of EPS.

There are only a few reports of a Parkinson's disease (PD)-like phenotype in molecularly confirmed MJD patients [4-6], and thus this particular MJD phenotype remains poorly documented, namely from the genetic point of view. The cases reported in the literature showed an initial phenotype indistinguishable from PD and a levodopa positive response. Only after several years of progression the characteristic features of MJD, namely cerebellar signs, were observed. The parkinsonian phenotype has been suggested to be more common

* Correspondence: mcbettencourt@uac.pt

¹Center of Research in Natural Resources (CIRN), University of the Azores, Ponta Delgada, Portugal

Full list of author information is available at the end of the article

in MJD patients of African descent, although rare in those of European origin [7].

MJD phenotypes with EPS, particularly those with a PD-like phenotype, may result from epistatic effects of variants in other loci. As primary candidates are PD associated loci, namely *PARK2*, *LRRK2*, *PINK1*, *DJ-1*, *SNCA*, *MAPT*, and *APOE* (e.g. [8-10]). Variation in mitochondrial DNA (mtDNA) has also been shown to have an impact on neurodegenerative diseases' phenotype, and the *tRNA^{Gln}* T4336C mutation was previously associated with Alzheimer's disease (AD) and PD [11]. The main goal of this work was to describe two unrelated MJD patients displaying the parkinsonian triad, for which the genetic variation (mutations and/or polymorphisms) in PD associated loci was investigated.

Case Presentation

Out of a series of 70 molecularly confirmed MJD patients from the Azores Islands (Portugal), from whom DNA samples were available (extracted from blood samples, which were collected after obtaining written informed consent), two patients presenting the parkinsonian triad, and belonging to distinct MJD families (one from São Miguel Island and other from Graciosa Island), were identified.

Patient 1

Patient 1 is a 40 year-old female patient (Figure 1; III-4). At the age of 30 years (Table 1), she noticed slowness of movements. At examination, she had a poor mimic and marked bradykinesia. She responded well to L-dopa, which she maintained for 8 years. At this time she was hospitalized because of neurological aggravation and depression. She presented, besides a prominent parkinsonian syndrome with frequent on-off phenomena, cerebellar dysarthria and general incoordination, axial and upper limbs dystonia, upwards gaze limitation with upwards gaze nystagmus, generalized hyperreflexia and bilateral Babinski sign, as well as marked gait ataxia.




Table 1 Characteristics of Patient 1 and Patient 2

Characteristics	Patient 1	Patient 2
Age at Onset	30	33
Onset Mode	Pure PD signs	PD plus cerebellar signs?
Family history for PD features	Mother and grandfather	NP
ATXN3 (CAG)n tract length		
Normal Allele	14	29
Expanded Allele	72	72
PARK2 Gene Mutations	NP	NP
LRRK2 Gene Mutations	NP	NP
PINK1 Gene Mutations	NP	NP
DJ-1 Gene		
Mutations	NP	NP
Polymorphisms		
g.168_185del	Del/Del	Ins/Del
rs7517357	T/T	C/T
rs2641116	G/G	T/G
rs56327722	A/A	G/A
SNCA Gene		
REP1	261/261	261/261
MAPT Gene		
rs242557	A/G	G/G
Haplotype	H1/H2	H2/H2
APOE Gene		
genotype	ε2/ε3	ε2/ε3
mtDNA		
T4336C mutation	NP	NP
Haplogroup	H	H

NP - Not present

Her mother (Figure 1; II-3) also had exhibited a parkinsonian phenotype. By the age of 34, she noticed difficulty in walking and in the fine movements of the hands. First examined at 36, she had bradykinesia, including amimia, bilateral hypertonia, without tremor, nor incoordination. The gait was purely parkinsonian, with small steps and no balance of the arms. She responded well to L-dopa, reaching a normal neurological examination under 300 mg + 75 mg of the inhibitor. Examined 12 years later, she was still under L-dopa treatment. Besides her parkinsonian syndrome and extreme dyskinesias, she had a deep depression, a moderate gait and lower limbs' ataxia, cerebellar dysarthria, and marked upwards gaze limitation. The maternal grandfather of Patient 1 (Figure 1; I-1) had an onset at 63 years of age with slowly progressive gait ataxia, followed by dysarthria, diplopia and dysphagia. Examined the first time with 8 years of evolution, he had upwards gaze limitation and horizontal squint, moderate peroneal atrophy with generalized arreflexia, plantars in flexion, slight dysmetria in the upper limbs, marked dysmetria

in the lower limbs and ataxic gait possible with unilateral support. Four years later mild Parkinson's signs were observed, with resting tremor in the upper limbs and bilateral rigidity. He died two years later aged 77 years.

Patient 2

Patient 2 is a 38 year-old male patient (Figure 2: II-16). He reported complaints of left hand's tremor since he was 33 years old. In neurological examination at the age of 35 years, he presented slight tremor of the left hand and of the L-lower limb. There was a cog-wheel rigidity of the left side, slight ataxia, hyperreflexia and right Babinski sign. The EPS responded consistently to L-dopa. His MRI was normal. His father (Figure 2: I-1) was only observed after 18 years of disease progression (reported onset at 42 years old), but did not present EPS. Furthermore, none of the remaining affected siblings (Figure 2: II-4, II-9, and II-12) present parkinsonian features.

Molecular analysis

The *ATXN3* (CAG)_n tract size was determined as previously described [12]. All the exons and exon-introns boundaries of *PARK2*, *LRRK2*, *PINK1* and *DJ-1* genes were amplified by PCR. The resulting PCR products were purified by Exo-SAP treatment (GE Healthcare) and sequenced using the BigDye[®] Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Multiplex Ligation-Dependent Probe Amplification (MLPA) was used, according to Djarmati *et al.* [13], to search for large deletions or duplications in *PARK2*, *PINK1* and *DJ-1*. The *SNCA* REP1 allele-length variants were genotyped as previously described [9]. In *MAPT* locus, a SNP (rs242557) was genotyped by a custom Taqman assay according to the manufacturer's specifications, and its genotype was used to infer *MAPT* haplotypes. The *APOE* genotypes were determined according to Bettencourt *et al.* [14]. The mtDNA haplogroup was established as previously described by Santos *et al.* [15], and the region encompassing the T4336C mutation was amplified by PCR, according to Ramos *et al.* [16]. PCR

products were purified using the JETQUICK PCR Purification Spin Kit (Genomed) and sequenced, using the BigDye[®] Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), according to the manufacturer's specifications.

Both patients presented 72 CAG repeats in their expanded *ATXN3* allele (Table 1), which corresponds to the mode for the expanded alleles in the Azorean MJD series [17]. In *PARK2*, *LRRK2*, *PINK1*, *DJ-1* and mtDNA *tRNA^{Gln}*, no known pathogenic mutations were detected in the analyzed regions (Table 1). Several polymorphisms were found at the *DJ-1* gene (Table 1). Results for the *SNCA* REP1, *MAPT* and *APOE* loci, as well as for the mtDNA haplogroup, are shown in Table 1.


Although MJD presents EPS more frequently than the other ADCAs, the manifestation of the parkinsonian triad is rare, being present in less than 3% of the analyzed MJD series. Even though the two studied cases are distinct, the grandfather-mother-daughter transmission in the family of Patient 1, and the heterogeneity presented by the family of Patient 2, suggests a supporting genetic background, e.g. modifier gene(s).

Mutations in the *PARK2* gene have been described as the most frequent in the cases of early onset PD [18]. However, none of the studied patients presented mutations in this gene. Similarly, no mutations were identified in *LRRK2*, *PINK1* and *DJ-1* genes, or in position 4336 of mtDNA.

Given the fact that both patients belong to a typically European mtDNA haplogroup [15], the hypothesis of an African background, in which the parkinsonian phenotype seems more common [7], was not supported, at least in terms of maternal origin.

Association studies have shown that certain alleles of the *SNCA* REP1 locus, as well as the presence of two copies of *MAPT* H1, increase the risk of PD (e.g. [9,10]). In the patients analyzed, however, the homozygosity for the 261 allele (the commonest among Caucasians [9]), and the presence of at least one *MAPT* H2 was confirmed.

Although previous studies [19,20] failed to find an association between *DJ-1* g.168_185del polymorphism



and PD, De Marco *et al.* [21], using a larger series of PD patients, have reported that several *DJ-1* polymorphisms, including those observed in the present study and reported in Table 1, are significantly associated with PD.

The *APOE* ϵ 2 has been associated with increased risk of sporadic PD [8], and with an earlier onset of PD (e.g. [22]). The studied patients presented both the *APOE* ϵ 2/ ϵ 3 genotype.

In non-Parkinsonian patients (N = 55) from the Azorean MJD series (data not shown), the *DJ-1* g.168_185del was found in 23% of the alleles, not differing from the frequency of this deletion in other non-Parkinsonian Caucasian populations studied previously (e.g. [19-21]). The *APOE* ϵ 2 allele was present in only 4% of the alleles, which corresponds to a lower frequency than the one previously reported for this allele in the general Azorean population [14]. Besides the two Parkinsonian MJD patients studied here, only 2 additional Azorean patients (non-Parkinsonian) carry both the *DJ-1* g.168_185del and the *APOE* ϵ 2 allele.

Conclusions

The present report, in these two MJD patients, adds information on this rare phenotype, by allowing a deeper knowledge of the clinical and genetic variation present in such particular cases. Analysis of both pedigrees supports a genetic background influence. Although we cannot conclude on the presence of associations by studying only two Parkinsonian patients, the present results are in agreement with previous studies on Parkinson's disease. The implication of these findings, on what concerns a possible epistatic effect of the *DJ-1* g.168_185del and the *APOE* ϵ 2 allele on the MJD phenotype deserves to be tested, using an appropriate study design, namely on what concerns adequate sized parkinsonian MJD series (presently unavailable, to our knowledge).

Consent

Written consent was obtained from both patients for the publication of this case report. A copy of written consent is available for review by the Editor-in-Chief of this journal.

Acknowledgements

This work was supported by "PRI-DMJ" (funded by Regional Government of the Azores), and "Transcriptional variation of the *ATXN3* gene as modulator of the clinical heterogeneity in Machado-Joseph disease (MJD)" (PIC/IC/83074/2007, funded by "Fundação para a Ciência e a Tecnologia" - FCT). C.B. [SFRH/BPD/63121/2009] and T.C. [SFRH/BPD/38659/2007] are postdoctoral fellows from FCT.

Author details

¹Center of Research in Natural Resources (CIRN), University of the Azores, Ponta Delgada, Portugal. ²Department of Biology, University of the Azores, Ponta Delgada, Portugal. ³Institute for Molecular and Cell Biology (IBMC),

University of Porto, Porto, Portugal. ⁴Laboratório de Biologia Molecular, Instituto de Enfermidades Neurológicas, Fundación Socio-Sanitaria de Castilla-La Mancha, Guadalajara, Spain. ⁵Unitat Antropologia Biológica, Dep. Biologia Animal, Biologia Vegetal i Ecologia, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain. ⁶Department of Neurology, Hospital São Sebastião, Feira, Portugal. ⁷Section of Medical Genomics, Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands. ⁸Department of Neurology, Hospital of Divino Espírito Santo, Ponta Delgada, Portugal. ⁹Department of Clinical Genetics, Hospital of D. Estefania, Lisbon, Portugal.

Authors' contributions

CB participated in the design of the study, carried out part of the molecular analysis and drafted the manuscript. CS, PR, TC, and MR participated in the molecular analysis. PC have collected part of the clinical data and contributed to draft the manuscript. TK and JV were involved in the sampling process and in the collection of the clinical data. PH participated in the design and discussion of the study. ML participated in the design and coordination of the study, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 5 May 2011 Accepted: 24 October 2011

Published: 24 October 2011

References

- Schols L, Peters S, Szymanski S, Kruger R, Lange S, Hardt C, Riess O, Przuntek H: **Extrapyramidal motor signs in degenerative ataxias.** *Arch Neurol* 2000, **57**(10):1495-1500.
- Coutinho P: **Doença de Machado-Joseph: Tentativa de definição.** PhD Dissertation, Instituto de Ciências Biomédicas Abel Salazar, Porto; 1992.
- Bettencourt C, Lima M: **Machado-Joseph Disease: from first descriptions to new perspectives.** *Orphanet J Rare Dis* 2011, **6**:35.
- Tuite PJ, Rogaeva EA, St George-Hyslop PH, Lang AE: **Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion.** *Ann Neurol* 1995, **38**(4):684-687.
- Gwinn-Hardy K, Singleton A, O'Suilleabhain P, Boss M, Nicholl D, Adam A, Hussey J, Critchley P, Hardy J, Farrer M: **Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family.** *Arch Neurol* 2001, **58**(2):296-299.
- Buhmann C, Bussopulos A, Oechsner M: **Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease.** *Mov Disord* 2003, **18**(2):219-221.
- Subramony SH, Hernandez D, Adam A, Smith-Jefferson S, Hussey J, Gwinn-Hardy K, Lynch T, McDaniel O, Hardy J, Farrer M, et al: **Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians.** *Mov Disord* 2002, **17**(5):1068-1071.
- Huang X, Chen PC, Poole C: **APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease.** *Neurology* 2004, **62**(12):2198-2202.
- Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, et al: **Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.** *JAMA* 2006, **296**(6):661-670.
- Wider C, Wszolek ZK: **Clinical genetics of Parkinson's disease and related disorders.** *Parkinsonism Relat Disord* 2007, **13** Suppl 3:S229-232.
- Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R, et al: **Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.** *Genomics* 1993, **17**(1):171-184.
- Bettencourt C, Fialho RN, Santos C, Montiel R, Bruges-Armas J, Maciel P, Lima M: **Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal).** *J Hum Genet* 2008, **53**(4):333-339.
- Djarmati A, Guzvic M, Grunewald A, Lang AE, Pramstaller PP, Simon DK, Kaindl AM, Vieregge P, Nygren AO, Beetz C, et al: **Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification.** *Mov Disord* 2007, **22**(12):1708-1714.

14. Bettencourt C, Montiel R, Santos C, Pavao ML, Viegas-Crespo AM, Lopes PA, Lima M: **Polymorphism of the APOE locus in the Azores Islands (Portugal)**. *Hum Biol* 2006, **78**(4):509-512.
15. Santos C, Lima M, Montiel R, Angles N, Pires L, Abade A, Aluja MP: **Genetic structure and origin of peopling in the Azores islands (Portugal): the view from mtDNA**. *Ann Hum Genet* 2003, **67**(Pt 5):433-456.
16. Ramos A, Santos C, Alvarez L, Nogues R, Aluja MP: **Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification**. *Electrophoresis* 2009, **30**(9):1587-1593.
17. Bettencourt C, Santos C, Montiel R, Kay T, Vasconcelos J, Maciel P, Lima M: **The (CAG)_n tract of Machado-Joseph Disease gene (ATXN3): a comparison between DNA and mRNA in patients and controls**. *Eur J Hum Genet* 2010, **18**(5):621-623.
18. Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, Uras A, Groen JL, Rizzu P, van Hilten JJ, et al: **Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease**. *Mov Disord* 2009, **24**(2):196-203.
19. Eerola J, Hernandez D, Launes J, Hellstrom O, Hague S, Gulick C, Johnson J, Peuralinna T, Hardy J, Tienari PJ, et al: **Assessment of a DJ-1 (PARK7) polymorphism in Finnish PD**. *Neurology* 2003, **61**(7):1000-1002.
20. Morris CM, O'Brien KK, Gibson AM, Hardy JA, Singleton AB: **Polymorphism in the human DJ-1 gene is not associated with sporadic dementia with Lewy bodies or Parkinson's disease**. *Neurosci Lett* 2003, **352**(2):151-153.
21. De Marco EV, Annesi G, Tarantino P, Nicoletti G, Civitelli D, Messina D, Annesi F, Arabia G, Salsone M, Condino F, et al: **DJ-1 is a Parkinson's disease susceptibility gene in southern Italy**. *Clin Genet* 2010, **77**(2):183-188.
22. Zarepari S, Camicioli R, Sexton G, Bird T, Swanson P, Kaye J, Nutt J, Payami H: **Age at onset of Parkinson disease and apolipoprotein E genotypes**. *Am J Med Genet* 2002, **107**(2):156-161.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2377/11/131/prepub>

doi:10.1186/1471-2377-11-131

Cite this article as: Bettencourt et al.: Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report. *BMC Neurology* 2011 **11**:131.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

